Kidney Cancer Treatment Options

Print
Brand NameGeneric NameHow it worksDrug CompanyFDA approvalMainly used
SutentSunitinibTargeted Therapy:
Tyrosine-Kinase Inhibitor (TKI) or VEGF inhibitor
Oral medication
Pfizer2006 approval for metastatic renal cell carcinoma (RCC); 2017 approval for RCC at high risk of recurrence1st line and as adjuvant treatment.
VotrientPazopanibTargeted Therapy: TKI, VEGF inhibitor
Oral medication
Novartis2012 approval for metastatic RCC1st line
InlytaAxitinibTargeted Therapy: TKI, VEGF inhibitor
Oral medication
Pfizer2012 approval for metastatic RCC after failure of one prior systemic therapy2nd or later line
CabometyxCabozantinibTargeted Therapy: TKI, VEGF and c-MET inhibitor
Oral medication
Exelixis2016 approval for metastatic RCC after prior therapy; 2017 approval for first line metastatic RCC.2nd line, also approved in 1st line for intermediate and poor risk
Lenvima/AfinitorLenvatinib/EveroliumsTargeted Therapy: TKI, VEGF inhibitor plus m-TOR inhibitor
Oral medication
Eisai2016 approval for metastatic RCC patients following one prior anti-angiogenic therapy2nd or later line
NexavarSorafenibTargeted Therapy: TKI, VEGF inhibitor
Oral medication
Bayer2005 approval for metastatic RCCLate line
AfinitorEverolimusTargeted Therapy: mTOR-Inhibitor
Oral medication
Novartis2009 approval for metastatic RCC after failure of treatment with sunitinib or sorafenib2nd or later line, now
primarily in combination with Lenvima
ToriselTemsirolimusTargeted Therapy: mTOR-Inhibitor InfusionPfizer2007 approval for metastatic RCCApproved for poor risk 1st line for select patients; but now rarely used given alternatives
OpdivoNivolumabImmunotherapy: Anti-PD1
Checkpoint-Inhibitor infusion
Bristol Myers Squibb (BMS)2015 approval for metastatic RCC patients following one prior anti-angiogenic therapy2nd or later line
Avastin/ Interferon (IFN)Bevacizumab /Interferon alfaVEGF-Antibody plus immunotherapy Infusion/ subcutaneous injectionGenentech2009 approval for metastatic RCC1st line approval, rarely used given limited efficacy and IFN side effects
ProleukinAldesleukin (also known as high-dose Interleukin-2 IL-2, HDIL-2)Immunotherapy Inpatient InfusionPrometheus1992 approval for metastatic RCC1st line, remains a treatment option with curative potential in selected patients

Lost Password

Register

Subscribe for updates!